drugset / Trial / NCT02067676

Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea

NCT02067676

Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to assess the safety of increasing doses of a potential vaccine against Campylobacter with and without Alhydrogel®, an aluminum hydroxide adjuvant. This study will also assess immune responses induced by the vaccine.

Timeline

Start
2014-04-21
Primary completion
2014-09-24
Completion
2016-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Aluminum hydroxide Unknown 125 ug Intramuscular
Subject CJCV1 Vaccine 2 ug Intramuscular
Subject CJCV1 Vaccine 5 ug Intramuscular
Subject CJCV1 Vaccine 10 ug Intramuscular

Indications